抗体药物靶点的功能通路研究分析  

The study of the functions and the pathway of the main targets in the antibody drugs

作　　者：李雪姣 刘海亮 张凤民[1] 宋武琦[1] Li Xuejiao;Liu Hailiang;Zhang Fengmin;Song Wuqi(Department of Microbiology,Harbin Medical University,Wu Lien-Teh Institute,The Heilongjiang Key Laboratory of Immunity and Infection,The Key Laboratory of Pathogenic Biology,Heilongfiang Higher Education Institutions,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学微生物学教研室,伍连德研究所,黑龙江省免疫与感染重点实验室,黑龙江省普通高校病原生物学重点实验室,150081

出　　处：《国际免疫学杂志》2018年第4期439-442,共4页International Journal of Immunology

基　　金：国家自然科学基金（81773267）;黑龙江省应用技术研究与开发计划项目（PS13H14）;中俄医学研究中心转化医学专项基金项目（CR201405）

摘　　要：自1975年杂交瘤技术的产生,以及随后1986年第一个鼠源抗体成功上市.截止到2017年,抗体药物30多年以来得到了飞速的发展.抗体药物对应靶点的功能、通路的研究越来越清晰,这使得抗体药物靶点的相关通路上关键分子都可能成为新的靶点药物开发目标,也为抗体药物由单一靶点向多靶点、抗体高效性等方面指明了方向.抗体药物主要应用于实体肿瘤、血液性肿瘤、自身免疫性疾病及过敏性疾病等的治疗. The technology of hybrid tumor was generated in 1975 following by the successful launch of the first mouse antibody in 1986. By the year 2017,antibody drugs have been developing rapidly over the past 30 years. The research on the function and pathway of the antibody drug targets become more clear,which makes the key molecules on the related pathway of the antibody drug targets to become the new target for drug develop-ment and indicates the development direction of the antibody drug from a single target to the multi targets and the high efficiency of the antibody. The Antibody drugs are mainly used in the treatment of solid tumor,blood tumor,autoimmune diseases and allergic diseases.

关 键 词：抗体药物 靶点 通路 

分 类 号：R392[医药卫生—免疫学]